Influenza Virus Replicated in Mammalian Cell Culture and Vaccine Production (SJ-94-0007)



Technology Name
(St. Jude Reference #)
Influenza Virus Replicated in Mammalian Cell Culture and Vaccine Production (SJ-94-0007)
Description A method for growing influenza virus to a high
titer in mammalian cell culture by maintaining a
constant trypsin concentration is provided. The
resulting virus is suitable for use in vaccines
after inactivation or attenuation.  This method
could be used to manufacture clinical grade
influenza vaccine that may be used either
prophylactically to prevent infection or
therapeutically to treat infected patients. 
Keywords Influenza virus, vaccine production, mammalian cell culture, tryspin
Granted Patents or Published Applications U.S. Patent Nos. 5,824,536; 6,344,354
Related Scientific References

Govorkova, E et al., “Replication of Influenza A viruses in a green monkey kidney continuous cell line (Vero)” J. Infect. Dis. 172:250-253 (July 1995);

Katz, JM and Webster, RG, “Antigenic and Structural characterization of multiple sub-populations of H3N2 influenza virus from an individual” Virol. 165(2):446-456 (1988);

Katz, JM and Webster RG, “Efficacy of inactivated influenza A virus (H3N2) vaccines grown in mammalian cells or embryonated eggs” J. Infect. Dis. 160(2):191-198 (1989);

Kaverin, NV and Webster, RG “Impairment of multicycle influenza growth in Vero (WHO) cells by loss of trypsin activity” J. Virol. 69(4):2700-2703 (April 1995).

Licensing Opportunities We are currently seeking non-exclusive licensees in all fields.

 

Contact the Office of Technology Licensing (Phone: 901-595-2342, Fax: 901-595-3148) for more information.

 

Last update: January 2008